In mouse models, interfering with the CXCR4–CXCL12 axis promoted CD8+ T cell infiltration and reduced CXCL12-mediated migration of lymphocytes and MDSCs to the TME, as well as inhibited tumor revascularization following anti-angiogenic therapy [320]. The gene discussed is CXCL12; the disease is neoplasm.